<DOC>
	<DOC>NCT00724334</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.</brief_summary>
	<brief_title>A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis</brief_title>
	<detailed_description>SAR302503 (TG101348) is a potent small molecule inhibitor of Janus kinase 2 (JAK2). This is an extension study for a first-in-man, dose escalation study (MF-TG101348-001). The safety, tolerability and clinical activity of SAR302503 (TG101348) in subjects with myelofibrosis will be evaluated.</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Completion of MFTG101348001 study Diagnosis of myelofibrosis At least 18 years of age Any acute or chronic medical abnormality that may increase the risk associated with study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>myelofibrosis</keyword>
</DOC>